bioRxiv Science⌕ Search

Biology subjects

Settembre, C.

Publications and source records attributed to Settembre, C..

2 recordsLinked to original sources

The ZNF687 mutation of Paget's disease associated with giant cell tumour causes severe bone remodelling alteration as a result of a deregulated osteoclast transcriptional program

Pagets disease (PDB) is a late-onset bone remodelling disorder with a broad spectrum of symptoms and complications. One of the most aggressive forms is caused by the P937R mutation in the ZNF687 gene. Although the genetic involvement of ZNF687 in PDB has been extensively studied, the molecular mechanisms underlying this association remains unclear. Here, we describe the first Zfp687 knock-in mouse model and demonstrate that the mutation recapitulates the PDB phenotype, showing a severe bone remodelling alteration. Through micro-computed tomography analysis, we observed that 8-month-old mice showed a mainly osteolytic phase, with a significant decrease in the trabecular bone volume affecting the femurs and the vertebrae of both heterozygous and homozygous mutant mice. In contrast, osteoblast activity was deregulated, beginning to produce disorganised bone. Noteworthy, this phenotype became pervasive in 16-month-old mice, where osteoblast function overtook bone resorption as the predominant event, as highlighted by the presence of woven bone in histological analyses, consistent with the PDB phenotype. Furthermore, we detected osteophytes and intervertebral disc degeneration, outlining for the first time the link between osteoarthritis and PDB in a PDB mouse model. Finally, we generated CRISPR-Cas9-based Zfp687 knock-out RAW 264.7 cells, and noted a remarkable impairment of osteoclast differentiation capacity, reinforcing the relevance of Zfp687 during this process. RNA-sequencing on wild type and KO clones identified a set of genes involved in osteoclastogenesis under the control of Zfp687, i.e., Tspan7, Cpe, Vegfc, and Ggt1. Thus, this study established an essential role of Zfp687 in the regulation of bone remodelling, and may offer the potential to therapeutically treat PDB.

cell biology↗

Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders.

Urea cycle disorders (UCD) are inherited defects in clearance of waste nitrogen with high morbidity and mortality. Novel and more effective therapies for UCD are needed. Studies in mice with constitutive activation of autophagy unraveled Beclin-1 as druggable candidate for therapy of hyperammonemia. Next, we investigated efficacy of cell penetrating autophagy inducing Tat-Beclin-1 (TB-1) peptide for therapy of the two most common UCD, namely ornithine transcarbamylase (OTC) and argininosuccinate lyase (ASL) deficiencies. TB-1 reduced urinary orotic acid and hyperammonemia, and improved survival under protein-rich diet in spf-ash mice, a model of OTC deficiency (proximal UCD). In AslNeo/Neo mice, a model of ASL deficiency (distal UCD), TB-1 increased ureagenesis, reduced argininosuccinate, and improved survival. Moreover, it alleviated hepatocellular injury and decreased both cytoplasmic and nuclear glycogen accumulation in AslNeo/Neo mice. In conclusion, Beclin-1-dependent activation of autophagy improved biochemical and clinical phenotypes of proximal and distal defects of the urea cycle.

genetics↗